CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

HP:0030079: Cervix cancerHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1343 modification of the planned therapeutic management Wiki 1.00
drug752 Nitazoxanide Wiki 0.58
drug612 Ivermectin Wiki 0.41
drug262 Chloroquine Wiki 0.38

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D001943 Breast Neoplasms NIH 1.00
D010051 Ovarian Neoplasms NIH 1.00
D014846 Vulvar Neoplasms NIH 1.00
D002583 Uterine Cervical Neoplasms NIH 1.00
D014594 Uterine Neoplasms NIH 1.00
D014625 Vaginal Neoplasms NIH 1.00
D009369 Neoplasms, NIH 0.30

Correlated HPO Terms (6)

Name (Synonyms) Correlation
HP:0100615 Ovarian neoplasm HPO 1.00
HP:0010784 Uterine neoplasm HPO 1.00
HP:0100650 Vaginal neoplasm HPO 1.00
HP:0030416 Vulvar neoplasm HPO 1.00
HP:0003002 Breast carcinoma HPO 1.00
HP:0002664 Neoplasm HPO 0.30

There is one clinical trial.

Clinical Trials

1 Impact of the COVID-19 Pandemic on Changes in Therapeutic Strategies in Gynecological Oncology

The current infection with the Coronavirus SARS-CoV-2 (COVID-19) is an exceptional health situation which requires an adaptation of our management practices in gynecological oncology. Data from the literature suggest that infection with Coronavirus is serious in subjects with cancer with a risk of severe form 5 times higher than that of the population without cancer and a risk of death multiplied by 8. In addition, the risk of infection would be 3 times greater in case of cancer. Faced with the COVID-19 epidemic, the investigator must organize themselves to ensure continuity in the treatment of patients with gynecological cancer but also adapt our practices in the management (CPR, teleconsultation, adaptation of treatment or even postponement of treatment). The objective of the High Council of Public Health is to be able to ensure adequate oncological care avoiding any potential loss of chance concerning the care of cancer: people affected must, despite the pandemic, have care allowing the same level of curability (localized cancers) or the same life expectancy (advanced cancers). This must be done by limiting as much as possible the impact on the organization of the service, the organization of patient follow-up and the psychological impact that these possible modifications could have. The hypotheses of our study are that the exceptional health situation linked to this pandemic leads to a change in the care of patients with gynecological cancer associated with a psychological impact and increased anxiety of patients during their care. Despite the extent of the pandemic, very little existing data makes it possible to define recommendations with a sufficient level of evidence.

NCT04351139 Gynecologic Cancer Breast Neoplasm Female Uterine Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Vulvar Neoplasms Vaginal Neoplasms Other: modification of the planned therapeutic management
MeSH:Breast Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Uterine Neoplasms Vulvar Neoplasms Vaginal Neoplasms Neoplasms
HPO:Breast carcinoma Cervical polyp Cervix cancer Neoplasm Neoplasm of the breast Ovarian neoplasm Uterine neoplasm Vaginal neoplasm Vulvar neoplasm

Primary Outcomes

Description: modification of the planned therapeutic management

Measure: percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)

Time: Day O

HPO Nodes